Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Discover Oncology
Erschienen in: Discover Oncology 6/2018

18.08.2018 | Original Paper

Diagnostic Performance of F-18 Fluorocholine PET/CT for Parathyroid Localization in Hyperparathyroidism: a Systematic Review and Meta-Analysis

verfasst von: Seong-Jang Kim, Sang-Woo Lee, Shin Young Jeong, Kyoungjune Pak, Keunyoung Kim

Erschienen in: Discover Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

The purpose of the current study was to investigate the diagnostic performance of F-18 Fluorocholine (FCH) positron emission tomography/computed tomography (PET/CT) for localization of hyperfunctioning parathyroid gland in patients with hyperparathyroidism (HPT) through a systematic review and meta-analysis. The MEDLINE/PubMed and EMBASE database, from the earliest available date of indexing through April 30, 2018, were searched for studies evaluating the diagnostic performance of F-18 FCH PET/CT for localization of hyperfunctioning parathyroid gland in patients with HPT. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR−), and constructed summary receiver operating characteristic curves. Across eight studies (272 patients), the pooled sensitivity for F-18 FCH PET/CT was 0.90 (95% CI, 0.86–0.94) without heterogeneity (I2 = 7.1) and a pooled specificity of 0.94 (95% CI, 0.90–0.96) with heterogeneity (I2 = 79.8). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 5.3 (95% CI, 1.2–24.3) and negative likelihood ratio (LR−) of 0.15 (95% CI, 0.08–0.29). The pooled diagnostic odds ratio (DOR) was 38 (95% CI, 8–174). Hierarchical summary receiver operating characteristic (ROC) curve indicates that the areas under the curve were 0.9492 (SE, 0.0215). In meta-regression analysis, no definite variable was the source of the study heterogeneity. The current meta-analysis showed the high sensitivity and specificity of F-18 FCH PET/CT for localization of hyperfunctioning parathyroid gland. At present, the literature regarding the use of F-18 FCH PET/CT for localization of hyperfunctioning parathyroid gland remains still limited; thus, further large multicenter studies would be necessary to substantiate the diagnostic accuracy of F-18 FCH PET/for localization of hyperfunctioning parathyroid gland in patients with HPT.
Literatur
1.
2.
Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP (2008) Parathyroid carcinoma. J Bone Miner Res 23:1869–1880CrossRef
3.
Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA (1992) Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 71:197–205CrossRef
4.
Taillefer R, Boucher Y, Potvin C, Lambert R (1992) Detection and localization of parathyroid adenomas in patients with hyperparathyroidism using a single radionuclide imaging procedure with technetium-99m-sestamibi (double-phase study). J Nucl Med 33:1801–1807PubMed
5.
Hodolic M, Huchet V, Balogova S, Michaud L, Kerrou K, Nataf V, Cimitan M, Fettich J, Talbot JN (2014) Incidental uptake of 18F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiol Oncol 48:228–234CrossRef
6.
Cazaentre T, Clivaz F, Triponez F (2014) False-positive result in 18F-fluorocholine PET/CT due to incidental and ectopic parathyroid hyperplasia. Clin Nucl Med 39:e328–e330CrossRef
7.
Ishizuka T, Kajita K, Kamikubo K, Komaki T, Miura K, Nagao S, Nozawa Y (1987) Phospholipid/Ca2+-dependent protein kinase activity in human parathyroid adenoma. Endocrinol Jpn 34:965–968CrossRef
8.
Kluijfhout WP, Vorselaars WM, Vriens MR, Borel Rinkes IH, Valk GD, de Keizer B (2015) Enabling minimal invasive parathyroidectomy for patients with primary hyperparathyroidism using Tc-99m-sestamibi SPECT-CT, ultrasound and first results of 18F-fluorocholine PET-CT. Eur J Radiol 84:1745–1751CrossRef
9.
Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh QY, Vriens MR, de Keizer B, Hope TA, Glastonbury CM, Pampaloni MH, Suh I (2017) 18F Fluorocholine PET/MR imaging in patients with primary hyperparathyroidism and inconclusive conventional imaging: a prospective pilot study. Radiology 284:460–467CrossRef
10.
Thanseer N, Bhadada SK, Sood A, Mittal BR, Behera A, Gorla AKR, Kalathoorakathu RR, Singh P, Dahiya D, Saikia UN, Rao SD (2017) Comparative effectiveness of ultrasonography, 99mTc-sestamibi, and 18F-fluorocholine PET/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin Nucl Med 42:e491–e497CrossRef
11.
Taywade SK, Damle NA, Behera A, Devasenathipathy K, Bal C, Tripathi M, Agarwal S, Tandon N, Chumber S, Seenu V (2017) Comparison of 18F-fluorocholine positron emission tomography/computed tomography and four-dimensional computed tomography in the preoperative localization of parathyroid adenomas-initial results. Indian J Endocrinol Metab 21:399–403CrossRef
12.
Huber GF, Hüllner M, Schmid C, Brunner A, Sah B, Vetter D, Kaufmann PA, von Schulthess GK (2018) Benefit of 18F-fluorocholine PET imaging in parathyroid surgery. Eur Radiol 28:2700–2707CrossRef
13.
Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, QUADAS-2 Group (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536CrossRef
14.
Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM (2003) The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56:1129–1135CrossRef
15.
Thompson SG (1994) Why sources of heterogeneity in meta-analysis should be investigated. BMJ 309:1351–1355CrossRef
16.
Hamza TH, van Houwelingen HC, Stijnen T (2008) The binomial distribution of meta-analysis was preferred to model within-study variability. J Clin Epidemiol 61:41–51CrossRef
17.
Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58:982–990CrossRef
18.
Rutter CM, Gatsonis CA (2001) A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 20:2865–2884CrossRef
19.
Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM (1999) Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 282:1061–1066CrossRef
20.
Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31CrossRef
21.
Beheshti M, Hehenwarter L, Paymani Z, Rendl G, Imamovic L, Rettenbacher R, Tsybrovskyy O, Langsteger W, Pirich C (2018) 18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur J Nucl Med Mol Imaging 45:1762–1771. https://​doi.​org/​10.​1007/​s00259-018-3980-9 CrossRefPubMedPubMedCentral
22.
Fischli S, Suter-Widmer I, Nguyen BT, Müller W, Metzger J, Strobel K, Grünig H, Henzen C (2018) The significance of 18F-fluorocholine-PET/CT as localizing imaging technique in patients with primary hyperparathyroidism and negative conventional imaging. Front Endocrinol (Lausanne) 8:380CrossRef
23.
Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, Berdelou A, Hadoux J, Hescot S, Remy H, Baudin E, Schlumberger M, Deandreis D (2018) Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. https://​doi.​org/​10.​1007/​s00259-018-4018-z CrossRef
24.
Kluijfhout WP, Vorselaars WM, van den Berk SA, Vriens MR, Borel Rinkes IH, Valk GD, van Dalen T, de Klerk JM, de Keizer B (2016) Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl Med Commun 37:1246–1252CrossRef
25.
Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J (2014) 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur J Nucl Med Mol Imaging 41:2083–2089CrossRef
26.
Michaud L, Burgess A, Huchet V, Lefèvre M, Tassart M, Ohnona J, Kerrou K, Balogova S, Talbot JN, Périé S (2014) Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab 99:4531–4536CrossRef
27.
Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, Lefèvre M, Tassart M, Montravers F, Périé S, Talbot JN (2015) A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore) 94:e1701CrossRef
28.
Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, de Raucourt D, Grellard JM, Licaj I, Bardet S, Reznik Y, Clarisse B, Aide N (2018) F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging 45:658–666CrossRef
29.
Allendorf J, Kim L, Chabot J, DiGiorgi M, Spanknebel K, LoGerfo P (2003) The impact of sestamibi scanning on the outcome of parathyroid surgery. J Clin Endocrinol Metab 88:3015–3018CrossRef
30.
Lew JI, Solorzano CC (2009) Surgical management of primary hyperparathyroidism: state of the art. Surg Clin N Am 89:1205–1225CrossRef
31.
Johnson NA, Tublin ME, Ogilvie JB (2007) Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. AJR Am J Roentgenol 188:1706–1715CrossRef
32.
Bergenfelz AO, Jansson SK, Wallin GK, Mårtensson HG, Rasmussen L, Eriksson HL, Reihnér EI (2009) Impact of modern techniques on short-term outcome after surgery for primary hyperparathyroidism: a multicenter study comprising 2,708 patients. Langenbeck's Arch Surg 394:851–860CrossRef
33.
Perrier ND (2007) Impact of 25 hydroxyvitamin D deficiency in perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 142:1027–1029CrossRef
Metadaten
Titel
Diagnostic Performance of F-18 Fluorocholine PET/CT for Parathyroid Localization in Hyperparathyroidism: a Systematic Review and Meta-Analysis
verfasst von
Seong-Jang Kim
Sang-Woo Lee
Shin Young Jeong
Kyoungjune Pak
Keunyoung Kim
Publikationsdatum
18.08.2018
Verlag
Springer US
Erschienen in
Discover Oncology / Ausgabe 6/2018
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI
https://doi.org/10.1007/s12672-018-0347-4

Weitere Artikel der Ausgabe 6/2018

Discover Oncology 6/2018 Zur Ausgabe

Original Paper

Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation

Original Paper

Lower Circulating Androgens Are Associated with Overall Cancer Risk and Prostate Cancer Risk in Men Aged 25–84 Years from the Busselton Health Study

Original Paper

Neck Ultrasound in Patients with Follicular Thyroid Carcinoma

Original Paper

Mammographic Density and Circulating Sex Hormones: a Cross-Sectional Study in Postmenopausal Korean Women

Original Paper

Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells

Original Paper

The Importance of CYP19A1 in Estrogen Receptor-Positive Cholangiocarcinoma

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise